1、$Five Prime(FPRX)$\$Pandion Therapeutics(PAND)相继被并购,可否燃起医药板块的热情?
2、$Talis Biomedical(TLIS)$ 新股破发,是否有配置价值?
$快手-W(01024)$查看全文
chuminhua2021-03-04 23:29
3月4日,安进(Amgen)宣布将以19亿美元收购Five Prime。Five Prime的核心产品为FGFR2b抗体bemarituzumab等。再鼎医药于2017年以500万美元预付款+3900万美元里程碑金额引进Bemarituzumab的大中华区权益。$安进(AMGN)$ $Five Prime(FPRX)$查看全文
产业链观察2021-03-04 22:35
药闻| 2021年3月4日,- $安进(AMGN)$ 和$Five Prime(FPRX)$ (一家临床阶段的生物技术公司,专注于开发免疫肿瘤以及针对性癌症疗法),今天宣布了一项协议,安进公司将以每股38.00美元的现金价格收购Five Prime Therapeutics ,相当于约19亿美元的股权价值。
此次收购将Five Prime的创新产品线添...查看全文
Replix锐璞美股2021-03-04 22:03
$Five Prime(FPRX)$ 被收购!
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime ...查看全文
chuminhua2020-11-12 22:14
Five Prime Therapeutics日前宣布,其“first-in-class”靶向FGFR2b的单克隆抗体疗法bemarituzumab(FPA144),与化疗联用,在一线治疗晚期胃癌或胃食管连接部(GEJ)癌患者的2期临床试验中获得积极结果。这些患者的肿瘤为FGFR2b阳性,HER2阴性。新闻稿指出,这是首个表明针对FGFR2b的靶向治疗可能...查看全文
$Five Prime(FPRX)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-02-26 AccNo: 0001564590-19-004472 Size: 12 MB 网页链接
$Five Prime(FPRX)$ 美东时间 2019-02-26 盘后 披露财报,预期EPS -1.3 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-14 AccNo: 0000930413-19-000564 Size: 76 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-14 AccNo: 0000921895-19-000475 Size: 209 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0000315066-19-001014 Size: 8 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0000093751-19-000075 Size: 8 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-12 AccNo: 0000902219-19-000156 Size: 37 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-11 AccNo: 0000932471-19-004485 Size: 34 KB 网页链接
$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-04 AccNo: 0000215457-19-004023 Size: 13 KB 网页链接
$Five Prime(FPRX)$ 8-K - Current report Filed: 2019-01-15 AccNo: 0001193125-19-009759 Size: 27 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接